All In Biotech

Drug Trial Radar · NCT05658510

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

Efficacy And Safety of BXCL501 Evaluated For At-Home Use In A Multisite Double-Blind Placebo-Controlled Trial For Agitation Associated With Schizophrenia And Bipolar Disorder

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 452 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

452

Actual

Start

Nov 21, 2022

Primary completion

Aug 15, 2025

Study completion Aug 15, 2025

Sponsor

Lead sponsor
BioXcel Therapeutics IncIndustry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials
First posted
Dec 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.

Conditions

  • Agitation,Psychomotor
  • Bipolar I Disorder
  • Bipolar II Disorder
  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorders

Interventions

  • BXCL501Drug

    Sublingual Film

  • Matching PlaceboDrug

    Sublingual Placebo Film

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Change from baseline in Positive and Negative Syndrome Scale - Excited (PEC) total scoreTime frame: 2 hours
  2. Part 2: The incidence of SAEs and TEAEs compared with placebo.Time frame: Through study completion, an average of 12 weeks

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • BioXcel Clinical Research Site 113

    Bellflower, California

  • BioXcel Clinical Research Site 128

    Cerritos, California

  • BioXcel Clinical Research Site 110

    Culver City, California

  • BioXcel Clinical Research Site 108

    Garden Grove, California

  • BioXcel Clinical Research Site 117

    Lemon Grove, California

  • BioXcel Clinical Research Site 121

    Los Angeles, California

  • BioXcel Clinical Research Site 123

    Oceanside, California

  • BioXcel Clinical Research Site 104

    Orange, California

  • BioXcel Clinical Research Site 133

    Rancho Cucamonga, California

  • BioXcel Clinical Research Site 114

    Riverside, California

  • BioXcel Clinical Research Site 129

    Denver, Colorado

  • BioXcel Clinical Research Site 131

    Miami, Florida

  • BioXcel Clinical Research Site 124

    Miami, Florida

  • BioXcel Clinical Research Site 130

    Elgin, Illinois

  • BioXcel Clinical Research Site 103

    Gaithersburg, Maryland

  • BioXcel Clinical Research Site 118

    Las Vegas, Nevada

  • BioXcel Clinical Research Site 137

    Las Vegas, Nevada

  • BioXcel Clinical Research Site 105

    Berlin, New Jersey

  • BioXcel Clinical Research Site 122

    Beachwood, Ohio

  • BioXcel Clinical Research Site 136

    Austin, Texas

  • BioXcel Clinical Research Site 102

    DeSoto, Texas

  • BioXcel Clinical Research Site 125

    Irving, Texas

  • BioXcel Clinical Research Site 127

    Plano, Texas

  • BioXcel Clinical Research Site 126

    Everett, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.